SCHEDULE 13G/A: Biotechnology Value Funds Report 9.99% Stake in 4D Molecular Therapeutics

A group of investment funds and entities managed by Biotechnology Value Fund, including Mark N. Lampert, have reported a combined beneficial ownership of 9.99% in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Summary

• As of December 31, 2024, the Reporting Persons, including Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP, and related entities, collectively beneficially owned 4,834,297 shares of 4D Molecular Therapeutics, Inc. Common Stock.
• This aggregate ownership represents approximately 9.99% of the outstanding shares, calculated based on 46,227,709 shares outstanding as of November 12, 2024, plus 2,163,655 shares underlying certain pre-funded warrants held by the Reporting Persons.
• The Reporting Persons hold pre-funded warrants exercisable for an aggregate of 5,775,000 shares, with an exercise price of $0.0001 per share.
• A 'Pre-Funded Warrants Blocker' limits the exercise of these warrants such that beneficial ownership does not exceed 9.99% of the total outstanding shares, resulting in only 2,163,655 shares from these warrants being currently included in the beneficial ownership calculation.
• Mark N. Lampert, as a director and officer of BVF Inc., is deemed to beneficially own the same 4,834,297 shares, representing 9.99% of the class.
• The filing states that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: This is a factual report of beneficial ownership and does not contain performance or forward-looking statements to assess sentiment. The nature of the filing is neutral.

Positives

• The significant stake held by a specialized biotechnology investment group may signal confidence in 4D Molecular Therapeutics, Inc.'s long-term prospects.
• The investment group's passive stance, as indicated by the filing, suggests they are not currently seeking to disrupt company operations or management control.

Risks

• The 'Pre-Funded Warrants Blocker' limits the immediate full exercise of all held warrants, potentially capping the upside for the reporting persons if the share price significantly increases and they wish to convert more warrants.
• While generally passive, the explicit mention of potential activities 'solely in connection with a nomination under Rule 14a-11' indicates a reserved right to engage in director nominations, which could introduce governance-related discussions in the future.

Future Outlook

NA

Industry Context

This filing reflects a significant investment by a specialized biotechnology fund in 4D Molecular Therapeutics, Inc., a company operating within the biotechnology sector. Such investments are common as institutional investors seek to gain exposure to promising companies in high-growth industries like biotech.

Corporate Governance

Related Party Transactions

• The various reporting entities (Biotechnology Value Fund, BVF I GP LLC, Biotechnology Value Fund II, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert) are related parties, forming a group that collectively reports beneficial ownership.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by a specialized biotechnology fund may be viewed positively, potentially indicating a vote of confidence in the company's value and future prospects.
• Management: The filing clarifies that the investor group is generally passive, which may reduce concerns about immediate activist pressure, though the right to nominate directors is reserved.

Key Dates

Keywords

4D Molecular Therapeutics, Biotechnology Value Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, pre-funded warrants, institutional investment, biotechnology, investment funds